首页 | 本学科首页   官方微博 | 高级检索  
     

血液肿瘤多药耐药的研究进展
引用本文:张锦海,陈幸华. 血液肿瘤多药耐药的研究进展[J]. 中国实验血液学杂志, 2005, 13(6): 1151-1154
作者姓名:张锦海  陈幸华
作者单位:第三军医大学新桥医院血液科,重庆,400037
摘    要:
化疗是血液肿瘤的主要治疗手段,但目前存在的关键问题是肿瘤细胞对化疗药物产生多药耐药(MDR).这种现象由多种耐药机制导致,包括了如过度表达耐药相关蛋白的生化机制和涉及造血微环境的生理机制等.本文简要回顾了MDR的产生机制和逆转策略方面的研究进展,重点讨论了MDR的检测和结果分析,以及和造血微环境的关系.

关 键 词:血液肿瘤 多药耐药 造血微环境
文章编号:1009-2137(2005)06-1151-04
收稿时间:2004-11-29
修稿时间:2005-09-22

Progress of Studies on Multidrug Resistance in Hematological Malignancies--Review
ZHANG Jin-Hai,CHEN Xin-Hua. Progress of Studies on Multidrug Resistance in Hematological Malignancies--Review[J]. Journal of experimental hematology, 2005, 13(6): 1151-1154
Authors:ZHANG Jin-Hai  CHEN Xin-Hua
Affiliation:Department of Hematology, Xinqiao Hospital, The Third Military Medical University, Chongqing 400037, China.
Abstract:
Chemotherapy remains a major route of intervention in hematological malignancies. However,a key issue in the treatment of hematological malignancies is the development of multidrug resistance (MDR) to chemotherapeutic drugs. Several mechanisms may account for this phenomenon, including biochemical mechanisms, such as the overexpression of resistance-conferring proteins and physiological mechanisms involving the hematopoietic microenvironment. In this article the pathomechanism, diagnostic approach, interpretation of results from clinical samples and correlations with hemopoietic microenvironment were briefly reviwed. The aspects of development and problems in MDR study as well as detection methods for MDR were also discussed.
Keywords:hematological malignancy   multidrug resistance   hematopoietic microenvironment
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号